“Layer peeling” co-delivery system for enhanced RNA interference-based tumor associated macrophages-specific chemoimmunotherapy

Wang, Tianqi; Mu, Weiwei; Li, Feifei; Zhang, Jing; Hou, Teng; Pang, Xiuping; Yin, Xiaolan; Zhang, Na

doi:10.1039/d0nr04025h

Cited by 9 publications

(5 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In brief, IKKβ‐siRNA combined with DOX improved the microenvironment of tumor immunosuppression and enhanced the antitumor immune response with excellent synergistic tumor suppressive effects. [ 59 ]…”

Section: Polysaccharide‐based Stimulus‐responsive Nanomedicines For C...mentioning

confidence: 99%

“…In brief, IKKβ-siRNA combined with DOX improved the microenvironment of tumor immunosuppression and enhanced the antitumor immune response with excellent synergistic tumor suppressive effects. [59] Separate delivery of chemotherapeutic and immunological drugs to their respective targets is the precondition for achieving the desired therapeutic effect. Wang et al developed a dualcore-shell nanodelivery platform for the delivery of sorafenib (SF) and the TAM re-polarization agent IMD-0354 for tumor chemoimmunotherapy.…”

Section: Ph-responsive Nanomedicinementioning

confidence: 99%

See 1 more Smart Citation

Polysaccharide‐Based Stimulus‐Responsive Nanomedicines for Combination Cancer Immunotherapy

Liu

Yan

et al. 2023

Small

View full text Add to dashboard Cite

According to the World Health Organization, there were approximately 9.96 million deaths from cancer in 2020. Although researchers are actively searching for new treatments, the outcomes have been unsatisfactory, with limited improvement in the five-year survival rates. [2] Until now, immunotherapy has become one of the four pillars of clinical cancer treatment, along with surgery, chemotherapy, and radiotherapy. [3] It endows the body with the ability to eliminate tumors and prevent recurrence by stimulating the immune system, thus extending the survival time of patients. [4] Checkpoint inhibitors, pericyte therapy, lymphocyte-promoting cytokines, agonistic antibodies against co-stimulatory receptors, and cancer vaccines have been developed in recent years. [5] Due to the limited targeting and inherent toxicity of immune medicines, systemic use may result in autoimmune illness or non-specific inflammation. [6,7] In addition, tumor heterogeneity, clonal diversity, complex genetic mutations, and complex microenvironment all contribute to the poor outcomes of current tumor treatments. [8,9] Fortunately, previous studies have demonstrated that chemotherapy, photodynamic therapy (PDT), and photothermal therapy (PTT) can induce immunogenic cell death (ICD), which can enhance the immunotherapy effect. [10,11] However, the precise delivery of the co-therapeutic agents to the tumor site becomes the main challenge. [12] The rapid development of nanotechnology has promoted the application of nanomedicines in tumor therapy. [13] Nanomedicines can accumulate at tumor sites via the enhanced permeability and retention (EPR) effect and deliver drugs to specific tumor cells, thereby reducing off-target toxicity. [14,15] Notably, stimulus-responsive nanomedicines as a promising drug delivery method have received more and more attention. [16,17] The smart nano-platforms can achieve rapid drug release in response to external stimulus (ultrasound, mechanical stimuli, magnetic fields, lasers, etc.) or internal stimulus in the tumor microenvironment (TME) (weak acidity, high glutathione (GSH) levels, reactive oxygen species (ROS), enzymes, adenosine triphosphate (ATP), etc.), thus improving tumor treatment outcomes. [18] Polysaccharides, a family of potential biomaterials, possess unique advantages such as unique physicochemical properties, Cancer immunotherapy is a promising antitumor approach, whereas nontherapeutic side effects, tumor microenvironment (TME) intricacy, and low tumor immunogenicity limit its therapeutic efficacy. In recent years, combination immunotherapy with other therapies has been proven to considerably increase antitumor efficacy. However, achieving codelivery of the drugs to the tumor site remains a major challenge. Stimulus-responsive nanodelivery systems show controlled drug delivery and precise drug release. Polysaccharides, a family of potential biomaterials, are widely used in the development of stimulus-responsive nanomedicines due to their unique physicochemical properties, biocompatibility, and modifiab...

show abstract

Section: Polysaccharide‐based Stimulus‐responsive Nanomedicines For C...mentioning

confidence: 99%

Section: Ph-responsive Nanomedicinementioning

confidence: 99%

Polysaccharide‐Based Stimulus‐Responsive Nanomedicines for Combination Cancer Immunotherapy

Liu

Yan

et al. 2023

Small

View full text Add to dashboard Cite

show abstract

“…Concurrently, the critically activated NF- k B (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling pathway, which affected the depolarization process of TAM, was influenced by IKKβ (inhibitor kappa B kinase β). As a consequence of this, focused administration of siRNA- IKK to M2-type TAMs can improve anti-tumor efficacy and significantly activate M2-type TAMs' ability to repolarize [52] .…”

Section: The Pharmacological Actions Of Sirna Drugs For Remodeling Tmementioning

confidence: 99%

Remodeling the tumor immune microenvironment via siRNA therapy for precision cancer treatment

Jiang,

Qi,

Yang

et al. 2023

Asian Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…Zhang et al developed a cell membrane and mitochondria stepwise targeting nanoparticle, with preferential drug delivery to the tumor cells through active targeting mediated by chondroitin sulfate on the surface of nanoparticle, and subsequent mitochondrial targeting was achieved via TPP exposure due to pH response . Our previous studies have proven the feasibility of the stepwise targeting strategy. , Therefore, in this study, we used NGR polypeptides to mediate tumor tissue targeting, α-MSH to mediate tumor cells targeting, and Neu5Ac to mediate TIBs targeting to specifically increase the uptake of Ib by TIBs and DTX by tumor cells. Herein, a TIME reshaped hybrid nanocage consisting of a biomacromolecule shell and heterotargeted lipid nanoparticles cores was designed for the codelivery of Ib and DTX to TIBs and tumor cells separately (Scheme ).…”

Section: Introductionmentioning

confidence: 99%

“…36 Our previous studies have proven the feasibility of the stepwise targeting strategy. 37,38 Therefore, in this study, we used NGR polypeptides to mediate tumor tissue targeting, α-MSH to mediate tumor cells targeting, and Neu5Ac to mediate TIBs targeting to specifically increase the uptake of Ib by TIBs and DTX by tumor cells. Herein, a TIME reshaped hybrid nanocage consisting of a biomacromolecule shell and heterotargeted lipid nanoparticles cores was designed for the codelivery of Ib and DTX to TIBs and tumor cells separately (Scheme 1).…”

Section: Introductionmentioning

confidence: 99%

Depleting Tumor Infiltrating B Cells to Boost Antitumor Immunity with Tumor Immune-Microenvironment Reshaped Hybrid Nanocage

et al. 2022

Self Cite

View full text Add to dashboard Cite

Tumor infiltrating B cells (TIBs)-dependent immunotherapy has emerged as a promising method for tumor treatment. Depleting TIBs to boost antitumor immunity is a highly desirable yet challenging approach to TIBs-dependent immunotherapy. Herein, a tumor immune-microenvironment reshaped hybrid nanocage CPN-NLI/MLD coloaded with the Bruton’s tyrosine kinase inhibitor ibrutinib, and cytotoxic drug docetaxel was developed for stepwise targeting TIBs and tumor cells, respectively. The tumor microenvironment responsive CPN-NLI/MLD promoted charge reversal and size reduction under acidic conditions (pH < 6.5). The accumulation of CPN-NLI/MLD in tumor tissues was achieved through CD13 targeting, and cellular uptake was increased due to the differ-targeting delivery. Targeting of docetaxel to tumor cells was achieved by the interaction of α-MSH modified on inner docetaxel-particle MLD and melanocortin-1 receptor on the surface of tumor cells. Targeting of ibrutinib to TIBs was achieved by the interaction of Neu5Ac modified on inner ibrutinib-particle NLI and CD22 on the surface of TIBs. The boosted antitumor immunity was achieved mainly by the inhibition of Bruton’s tyrosine kinase activation mediated by ibrutinib, which reduced the proportion of TIBs, enhanced infiltration of CD8+ and CD4+ T cells, increased the secretion of immunogenic cytokines including IL-2 and IFN-γ, and inhibited the proliferation of regulatory T cells and secretion of immunosuppressive cytokines including IL-10, IL-4, and TGF-β. Furthermore, CPN-NLI/MLD improved the antitumor efficiency of chemoimmunotherapy by reshaping tumor immune-microenvironment by TIBs depletion. Taken together, CPN-NLI/MLD represents a promising method for effective tumor treatment and combination therapy by TIBs-dependent immunotherapy.

show abstract

“Layer peeling” co-delivery system for enhanced RNA interference-based tumor associated macrophages-specific chemoimmunotherapy

Abstract: RNA interference (RNAi)–based immunotherapy combined with chemotherapy has emerged as a promising therapeutic strategy for cancer treatment. The transport of siRNA and small molecular agents from tumor vascular to separate...

Cited by 9 publications

References 45 publications

Polysaccharide‐Based Stimulus‐Responsive Nanomedicines for Combination Cancer Immunotherapy

Polysaccharide‐Based Stimulus‐Responsive Nanomedicines for Combination Cancer Immunotherapy

Remodeling the tumor immune microenvironment via siRNA therapy for precision cancer treatment

Depleting Tumor Infiltrating B Cells to Boost Antitumor Immunity with Tumor Immune-Microenvironment Reshaped Hybrid Nanocage

Contact Info

Product

Resources

About